GoKawiilBEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.
The agreement will give Insilico $115 million up front, with the remainder subject to regulatory and commercial milestones, along with royalties on future sales, according to the companies' announcement Monday.
Insilico has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage, Alex Zhavoronkov, founder and CEO of Insilico, told CNBC. The company went public in Hong Kong in December. Its shares are up more than 50% year-to-date.
"In many ways, Lilly is better than us in some areas of AI," Zhavoronkov said, noting the U.S. pharma giant has "one person" who has brought biology, chemistry and automation under one roof. He added that as part of the deal, Insilico will join Lilly's Gateway Labs community for biotech development.
The two companies have worked together since signing an AI-based software licensing agreement in 2023.
"This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas," Andrew Adams, group vice president of Molecule Discovery at Lilly, said in a statement. He called Insilico's AI-enabled discovery "a powerful complement" to Lilly's clinical development.
Eli Lilly CEO David A. Ricks attended a high-level forum in Beijing earlier this month, just weeks after the company announced plans to invest $3 billion in China over the next decade. The company reported that slightly less than 3% of its revenue came from China last year.